Tirzepatide and semaglutide belong to the class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and are used in the treatment of type 2 diabetes and weight management. Despite their similarities, there are noteworthy differences.
- Tirzepatide targets two receptors, including the GLP-1, glucose-dependent insulinotropic polypeptide (GIP) This dual-receptor approach helps regulate blood sugar, increase insulin secretion, reduce glucagon production and slow gastric emptying, resulting in improved glycemic control and weight loss.
- Semaglutide primarily targets the GLP-1 receptor. By activating this receptor, semaglutide stimulates insulin secretion, suppresses glucagon release, slows gastric emptying and promotes a sense of fullness, leading to better blood sugar control and weight loss.